First Tracks Biotherapeutics (NASDAQ:TRAX) Price Target Raised to $70.00

First Tracks Biotherapeutics (NASDAQ:TRAX) had its price target raised by investment analysts at Wedbush from $60.00 to $70.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price target points to a potential upside of 51.75% from the company’s previous close.

TRAX has been the subject of several other reports. Wall Street Zen raised First Tracks Biotherapeutics to a “hold” rating in a research report on Saturday, May 2nd. JPMorgan Chase & Co. started coverage on First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They set an “overweight” rating and a $31.00 target price for the company. Zacks Research raised First Tracks Biotherapeutics to a “hold” rating in a report on Monday, April 27th. UBS Group increased their target price on First Tracks Biotherapeutics from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Monday. Finally, HC Wainwright raised their price objective on shares of First Tracks Biotherapeutics from $44.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, First Tracks Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $60.50.

First Tracks Biotherapeutics Trading Down 1.3%

Shares of TRAX opened at $46.13 on Thursday. First Tracks Biotherapeutics has a 12-month low of $14.72 and a 12-month high of $49.91. The firm has a market capitalization of $1.61 billion and a PE ratio of -25.07. The business’s 50-day simple moving average is $29.33.

First Tracks Biotherapeutics (NASDAQ:TRAX) last released its earnings results on Wednesday, August 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.21). Research analysts predict that First Tracks Biotherapeutics will post -3.42 earnings per share for the current fiscal year.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.